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Background: Dual antiplatelet therapy (DAPT) is a mainstay treatment for hospital survivors of 
an acute myocardial infarction (AMI). However, there are extremely limited data on the 
prescribing patterns of DAPT among patients hospitalized with AMI.   
Objective: To examine decade-long trends (2001-2011) in the use of DAPT versus antiplatelet 
monotherapy and patient characteristics associated with DAPT use. 
Methods: The study population consisted of 2,389 adults hospitalized with an initial AMI at all 
11 central Massachusetts medical centers on a biennial basis between 2001 and 2011. DAPT was 
defined as the discharge use of aspirin plus either clopidogrel or prasugrel. Logistic regression 
analysis was used to identify patient characteristics associated with DAPT use. 
Results: The average age of the study population was 65 years, and 69% of them were discharged 
on DAPT. The use of DAPT at the time of hospital discharge increased from 49% in 2001 to 74% 
in 2011; this increasing trend was seen across all age groups, both sexes, types of AMI, and in 
those who underwent a PCI. After multivariable adjustment, older age was the only factor 
associated with lower odds of receiving DAPT, while being male, receiving additional evidence-
based cardioprotective therapy and undergoing cardiac stenting were associated with higher odds 
of receiving DAPT.  
Conclusions: Between 2001 and 2011, the use of DAPT increased markedly among patients 
hospitalized with AMI. However, a significant proportion of patients were not discharged on this 
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Coronary artery disease has been the leading cause of death over the past decade. With the 
advancement of the management for this disease, several treatment modalities have been emerging 
that are contributing to better outcomes and quality of life, particularly among survivors of acute 
myocardial infarction. Dual antiplatelet therapy is a mainstay treatment for hospital survivors of 
an acute myocardial infarction, and guidelines are consistent in their recommendations for this 
therapy specially in recent years. In fact, dual antiplatelet therapy has been shown to reduce major 
adverse cardiovascular outcomes among survivors of acute myocardial infarction compared to 
antiplatelet monotherapy. However, there are extremely limited data on the prescribing patterns of 
dual antiplatelet therapy among patients hospitalized with acute myocardial infarction during 
recent years. Considering this, it is crucial to continuously monitor the implementation of 
evidence-based medicine by looking at trends in the use of cardioprotective drug therapies, such 
as DAPT, and examine patient characteristics that are associated with the receipt of this kind of 






CHAPTER I. INTRODUCTION 
Despite advances in the management of patients with acute and chronic forms of coronary 
artery disease, this disease remains a leading cause of morbidity and mortality worldwide (1). 
Antiplatelet medications are a mainstay therapy for the secondary prevention of an acute coronary 
syndrome as these therapies have been consistently shown to reduce cardiovascular morbidity and 
mortality (2, 3). Moreover, dual antiplatelet therapy (DAPT), where aspirin (ASA) is combined 
with the use of a P2Y12 receptor inhibitor (clopidogrel, prasugrel or ticagrelor), provides stronger 
platelet inhibition than a single antiplatelet medication. Use of DAPT has been shown to lead to a 
greater reduction in recurrent major adverse cardiovascular events in patients with an acute 
coronary syndrome as well as among those undergoing a percutaneous coronary intervention with 
stable coronary artery disease compared with aspirin monotherapy (4-9).  
Currently, American College of Cardiology/American Heart Association (10) and 
European Society of Cardiology guidelines (11) recommend dual antiplatelet therapy for effective 
secondary prevention among hospital survivors of an acute coronary syndrome, regardless of the 
revascularization intervention implemented. It remains of importance to continuously monitor the 
use of evidence-based therapy with antiplatelet medications, most notably DAPT, for the 
management of survivors of an acute coronary event. However, there are limited published data in 
the United States that has described changes over time in the use of, and factors associated with, 
DAPT in patients hospitalized with an acute myocardial infarction (AMI) (12).     
The primary objective of this observational study was to describe changes over time in the 




an initial AMI at all 11 metropolitan Worcester medical centers on a biennial basis between 2001 
and 2011. Our secondary study objective was to describe the characteristics of patients treated with 
DAPT versus aspirin monotherapy during the decade-long period under study and whether there 






CHAPTER II. METHODS  
Data for this investigation were derived from the Worcester Heart Attack Study (13). This 
is an ongoing population-based investigation that is examining long-term trends in the incidence, 
hospital, and post-discharge case-fatality rates of AMI among residents of central Massachusetts 
hospitalized at all greater Worcester medical centers. The medical records of residents of the 
Worcester metropolitan area hospitalized for possible AMI were individually reviewed on an 
approximate biennial basis and a diagnosis of AMI was validated with pre-defined criteria (14). 
Data Collection 
Demographic, clinical, and in-hospital management data were abstracted from hospital 
medical records of geographically eligible patients with confirmed AMI by trained study 
physicians and nurses. Information was collected about patient's age, sex, comorbidities (e.g., 
diabetes, hypertension, stroke, chronic kidney disease, atrial fibrillation), AMI order (initial versus. 
prior) and type ((ST-elevation Myocardial Infarction (STEMI) versus non-ST-elevation 
Myocardial Infarction (NSTEMI)), significant in-hospital AMI-related complications, in-hospital 
pharmacologic management and receipt of diagnostic/interventional procedures.  
Details regarding the antiplatelet regimen (DAPT or monotherapy) given at the time of 
hospital discharge were also obtained. DAPT was defined as the receipt of a combination of ASA 
and a P2Y12 receptor inhibitor (clopidogrel or prasugrel) at the time of hospital discharge, while 
antiplatelet monotherapy was defined as being prescribed either ASA or clopidogrel alone at the 
time of hospital discharge. Since ticagrelor, another P2Y12 receptor inhibitor, was not approved 




wanted to compare the characteristics of patients who received DAPT versus monotherapy, we 
excluded patients who did not receive any form of antiplatelet therapy. Moreover, since current 
clinical guidelines recommend DAPT for up to 12 months after a PCI with stent implantation 
before switching to monotherapy (10), we only included patients with an initial episode of AMI. 
In addition, because the addition of DAPT to oral anticoagulation therapy leads to a two to three-
fold increase in bleeding risk (15), patients who were also treated with anticoagulant therapy were 
excluded from the present investigation. Moreover, we excluded subjects who had coronary artery 
bypass graft (CABG) in this study due to their high risk of bleeding. Moreover, we collected data 
on the type of hospital that the patients were admitted to (teaching vs. non-teaching) as well as 
receipt of evidence-based medical therapy (beta blockers, statins and angiotensin-converting 
enzyme inhibitors/angiotensin receptor blockers). This study was approved by the Institutional 
Review Board at the University of Massachusetts Medical School. 
Data Analysis 
Differences in the distribution of demographic, medical history, and clinical characteristics 
between patients with AMI who received DAPT versus monotherapy were examined using chi-
square and t tests for discrete and continuous variables, respectively. The significance of changes 
over the decade-long study period in the use of antiplatelet therapy was examined using chi-square 
tests for trends. A logistic multivariable logistic regression approach was used to examine the 
association between several demographic and clinical characteristics with the receipt of DAPT 
during the patient’s index hospitalization for an initial AMI. Stratified analyses by type of AMI 




and all the models reported were deemed fit. All statistical analyses were performed with the use 
of STATA MP software, version 13.1, and a two-sided p-value of 0.05 or less was considered to 




CHAPTER III. RESULTS 
 
Study Population Characteristics 
The study population consisted of 2,389 hospital survivors of an initial, independently 
validated AMI at all 11 central Massachusetts medical centers. In this population, 1,657 patients 
(69.4%) were discharged from participating central Massachusetts hospitals on DAPT (Table 1). 
Patients who received DAPT at the time of hospital discharge were younger, more likely to be 
male, who developed a STEMI, and who underwent a cardiac catheterization and a PCI (Table 1). 
On the other hand, a smaller percentage of patients who received DAPT developed important 
hospital complications of AMI including heart failure. A greater proportion of patients who 
received monotherapy were previously diagnosed with various co-morbid medical, experienced a 
longer hospital stay, were less likely to be treated at teaching hospitals or receive evidence-based 
medical therapy for AMI and received thrombolytic therapy during their hospitalization (Table 1). 
 
Trends in the use of DAPT among hospital survivors of AMI  
The proportion of patients who presented with an initial AMI and received DAPT at the 
time of hospital discharge increased steadily over time from 49% in 2001 to 74% in 2011 (Figure 
1). This increase was seen across all age groups, in both sexes, in patients with a STEMI or an 
NSTEMI, and in those who underwent a PCI (Figure 1). After controlling for several demographic 
factors, comorbid conditions, hospital revascularization procedures, and complications of AMI, 




years under study (Table 2).  This trend was also seen after stratifying for the type of AMI and the 
receipt of a PCI (supplementary tables 1 and 2). 
In examining possible changing trends in DAPT use across different patient groups (Table 
3), the utilization of DAPT significantly decreased with advancing age, and was less often 
prescribed to women as compared with men. There was a significant increase during the years 
under study in the use of DAPT among patients with a STEMI or a NSTEMI, with different 
previously diagnosed co-morbidities, among those with and without prior antiplatelet use, and 
among those who underwent a PCI.  
 
Factors Associated with Receipt of DAPT at the Time of Hospital Discharge 
In the fully adjusted logistic regression model, patients who were between the ages of 65 
and 74 years were at significantly lower odds for receiving DAPT at the time of hospital discharge, 
while being male, receiving evidence-based medical therapy and undergoing a cardiac 
catheterization and a PCI were associated with a higher odds of receiving DAPT; undergoing a 
PCI was the strongest predictor of DAPT use (Table 4). Similar results were seen after stratifying 
for type of AMI (supplementary Table 3). However, after stratifying the data according to whether 
or not patients underwent a PCI, none of these demographic or clinical factors were associated 





CHAPTER IV. DISCUSSION 
Platelet adhesion and activation and subsequent aggregation represent the key targets for 
the secondary prevention of an acute coronary event. At the cellular level, aspirin and 
thienopyridines inhibit platelet activation through different mechanisms, and prior studies have 
shown the synergistic effects of DAPT on decreasing platelet activity and improving anti-
inflammatory effects compared with monotherapy alone in high-risk populations (16). Inasmuch, 
adding a thienopyridine to aspirin therapy has well-established benefits in the setting of an acute 
coronary syndrome, including patients who developed a STEMI or a non-STEMI (5, 17) and 
among those who underwent a PCI (9, 18), by reducing the risk of stent thrombosis, recurrent 
AMI, and cardiovascular mortality compared with aspirin alone. Hence, current guidelines 
recommend DAPT for at least 12 months among patients with an acute coronary syndrome 
regardless of the type of coronary revascularization procedure performed (10, 11). 
 
Trends in the use of DAPT among hospital survivors of AMI  
 To the best of our knowledge, there are very limited data and comparable studies 
describing trends in the use of different antiplatelet regimens for patients with AMI in the U.S. 
(19). The results of the present study demonstrate that the use of DAPT among residents of central 
Massachusetts hospitalized at all 11 greater Worcester medical centers for a first AMI has steadily 
increased during the decade-long period under study. This was seen among patients of different 
ages, both sexes, with different comorbidities, and after adjusting for several demographic factors, 




clinically important complications. This finding may reflect an increased awareness among 
clinicians to prescribe DAPT over monotherapy, and more optimal patient management practices.  
Data from several cardiovascular disease registries report overall usage of DAPT among 
patients discharged after an acute coronary syndrome in Europe and Canada to be between 60 and 
80%, depending in part on the characteristics of the study population, period under observation, 
and the type of acute coronary event examined (20, 21). Similar to our study, increases in the use 
of DAPT among hospital survivors of an AMI has also been seen in studies from Denmark and 
Sweden (22, 23), In one study of 28,449 patients who survived a first AMI between 2009 and 2012 
in Denmark, there was a slight increase in the proportion of patients who received DAPT from 
68% in 2009 to 73% in 2012 (22). Similar findings have been observed in a retrospective cohort 
study which used data from a Swedish national registry of patients hospitalized with AMI (24). In 
this investigation, there was a decrease in the proportion of patients not receiving DAPT, from 
33% in 2009 to 25% in 2013.  
Factors Associated with the Receipt of DAPT 
In examining differences in the characteristics of patients who received either DAPT or 
monotherapy, those who were treated with monotherapy appeared to be a sicker group of patients 
as reflected by their older age and presence of more co-morbid conditions; they also were less 
likely to be treated at teaching hospitals or receive evidence-based medical therapy for AMI. This 
may reflect suboptimal adherence to recommended guidelines at those hospitals included in the 
study, where subjects are not discharged on recommended therapies like DAPT. Moreover, we 




higher odds of being prescribed DAPT. Factors such as being a woman, of advanced age, and 
having chronic kidney disease have been associated with a higher risk for bleeding after an AMI 
(25-27). In addition, patients with a history of GI bleeding were less likely to have received DAPT 
during their acute hospitalization This is likely explained by the fact that antiplatelet therapy 
increases the risk of GI bleeding, and the risk of GI bleeding is further increased in patients on 
DAPT, likely due to prostaglandin inhibition by aspirin and decreased platelet aggregation by both 
aspirin and P2Y12 inhibitors (28). However, the resumption of antiplatelet therapy following an 
episode of GI bleeding has been shown to decrease mortality and the risk of recurrent ischemic 
events,  despite increasing the risk of episodes of minor or major bleeding (29). Inasmuch, 
antiplatelet therapy, particularly DAPT, should be considered among patients who are at risk for 
adverse events or have a history of GI bleeding, and the use of proton pump inhibitors should be 
strongly considered in these patients since these agents have been shown to reduce the risk of GI 
bleeding in patients on DAPT and has been strongly recommended as a Class I indication(10, 
30).  Inasmuch, the reasons for not prescribing DAPT to certain patient groups may have been 
based on physicians’ judgment given the high risk of bleeding among sicker patients, due to failing 
DAPT while in the hospital secondary to bleeding, medication costs, or less likely, to suboptimal 
care for these patients, as seen by the differences in receipt of evidence-based cardioprotective 
therapies.  
Despite the encouraging trends in increased use of DAPT over time, a considerable 
percentage of patients with a confirmed AMI failed to receive DAPT. In fact, we observed 




women were less likely to be prescribed this therapy than respective comparison groups. This is 
of particular concern since women and older individuals who develop an AMI have a worse 
prognosis and are at greater risk for developing a recurrent AMI compared with men and their 
younger counterparts (31, 32). Disparities in age and sex with respect to the management of AMI 
survivors have also been reported in other studies which have shown that women and older 
individuals were less likely to receive antiplatelet therapy and other cardio-protective medications 
than men and younger individuals (33).  
Despite the fact that the most recent year under study was 2011, there is usually a 
considerable lag time between guideline updates and widespread adoption of various AMI 
therapies, including DAPT, in clinical practice, which may explain the suboptimal utilization of 
DAPT during the period under study. For patients with a NSTEMI, recommendations for long-
term DAPT use post discharge have been established since 2002 (34). However, for patients with 
a STEMI, the recommendations for DAPT use have gained more strength in the last 5-10 years. 
Since the publication of the 2004 guidelines for the treatment of patients with a STEMI (35) that 
recommended DAPT only among those who received a stent, 2 trials have provided data 
supporting the expansion of the use of DAPT to those with a STEMI, irrespective of the type of 
reperfusion therapy utilized (36, 37). Not until 2007 did the ACC/AHA guidelines recommend the 
continued and long-term use of DAPT post discharge among survivors of an STEMI, regardless 
of revascularization therapy (Class IIa; Level of Evidence: C)) (38); this recommendation became 




ACC/AHA guidelines for the management of STEMI (39) and has been maintained in the most 
recent guidelines (10).  
 
Study Strengths and Limitations  
The current study has several strengths. First, we included patients from a well 
characterized urban community in central Massachusetts hospitalized with an independently 
validated first AMI at all hospitals in central Massachusetts. Moreover, this is the first U.S. study 
to examine trends in the discharge use of DAPT among a large number of patients hospitalized 
with AMI over a decade-long period who resided in a defined community. Additionally, we were 
able to control for a number of potentially confounding factors in examining patient characteristics 
associated with the receipt of DAPT in patients hospitalized with AMI.  
The limitations of our study include that the absence of data on the duration of DAPT for 
subjects who took it, which is the major area of debate in the recent years. In addition, we did not 
have data for use of the newest P2Y12 inhibitor, ticagrelor, as the drug was not approved until 
2013. Data on adherence to the regimen or switch between different antiplatelet medications, 





CHAPTER V. CONCLUSION 
 
In conclusion, the use of DAPT for the secondary prevention of AMI among patients with 
an AMI has increased over time, reflecting enhanced prescribing of evidence-based therapy. 
Despite the significant benefits on patient survival that have been observed with the use of DAPT 
compared with antiplatelet monotherapy, we observed that a significant proportion of patients 
discharged from the hospital after an AMI were not prescribed DAPT. Inasmuch, it is crucial to 
continuously monitor the implementation of evidence-based medicine by looking at trends in the 
use of cardioprotective drug therapies, such as DAPT, and examine patient characteristics that are 
associated with the receipt of this kind of therapy to enhance physicians’ awareness for subjects 
that may be undertreated with this therapy. Therefore, it is crucial to increase awareness among 
physicians to incorporate DAPT in the management of vulnerable group of patients, while varying 
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TABLES AND FIGURES 
 
Table 1. Baseline characteristics of hospital survivors of an initial acute myocardial infarction 
according to the receipt of antiplatelet therapy at the time of hospital discharge  
 
Characteristic DAPT  
(n = 1,657) 
Monotherapy 
(n = 732) 
p-value 
Age, mean (SD), years 61.8 (13.5) 70.9 (13.7) <0.001 
Male (%) 66.2 48.4 <0.001 
White (%) 88.3 88.8 0.72 
ST-segment elevation myocardial infarction (%) 46.7 25.4 <0.001 
Medical history (%)  
Chronic kidney disease 9.7 15.7 <0.001 
Chronic obstructive pulmonary disease 8.3 17.6 <0.001 
Diabetes mellitus 25.5 30.9 <0.01 
Heart failure 5.7 16.0 <0.001 
Hyperlipidemia 58.6 50.6 <0.001 
Hypertension 62.3 69.1 <0.01 
Peripheral vascular disease 9.7 13.2 <0.05 
Percutaneous coronary interventions 7.6 6.8 0.5 
Stroke 4.2 9.2 <0.001 
GI Bleeding 1.9 4.8 <0.001 




Antiplatelet therapy 29.7 33.6 0.056 
Hospital length of stay, days, mean (SD) 3.9 (3.1) 5.9 (4.5) <0.001 
Teaching hospital  97.65 86.8 <0.001 
Evidence-based medical therapy 57.9 27.3 <0.001 
Laboratory Data   
Serum cholesterol mg/dL, mean, (SD) 181.5 (43.0) 180.0 (48.0) 0.53 
Serum triglycerides mg/dl, mean (SD) 148.7 (110.7) 136.6 (97.2) <0.05 
Serum LDL mg/dl, mean (SD) 111.9 (39.03) 110.0 (44.74) 0.40 
Serum HDL mg/dl, mean (SD) 41.4 (11.8) 44.6 (20.73) <0.001 
Serum glucose, mg/dL, mean (SD) 158.5 (72.4) 168.9 (78.9) <0.01 
Hematocrit, % 41.2 (5.1) 40.2 (23.0) 0.10 
Troponin I, mean, (SD) 10.5 (54.8) 11.7 (58.7) 0.64 
eGFR mL/min/1.73m2, mean, (SD) 66.1 (19.5) 56.4 (21.3) <0.001 
Diagnostic/Interventional Procedure (%)  
Cardiac catheterization 90.1 48.9 <0.001 
Percutaneous coronary intervention  81.4 13.0 <0.001 
Thrombolytic therapy 3.7 4.8 0.23 
Hospital Complications (%)  
Cardiogenic shock 2.3 2.9 0.40 
Heart failure 17.1 36.6 <0.001 






Table 2. Trends in the receipt of DAPT at the time of hospital discharge among hospital survivors 
of an initial acute myocardial infarction (Worcester Heart Attack Study) 
 
Study year Odds ratio (95% confidence interval)*  
2001 Reference year  
2003 2.27 (1.41; 3.08) 
2005 3.34 (2.15; 4.98) 
2007 4.75 (2.84; 6.66) 
2009 3.70 (2.08; 4.94) 
2011 3.50 (2.07; 4.81) 
 
* Adjusted for age, sex, race, previously diagnosed comorbid conditions (hypertension, diabetes, heart failure, chronic kidney disease, peripheral 
vascular disease, stroke, chronic obstructive lung disease, GI bleeding, peptic ulcer disease), hospital development of a STEMI, coronary 
revascularization procedure, type of hospital, receipt of evidence-based therapy, and the development of hospital complications (stroke, heart 





Table 3. Changes over time in the receipt of DAPT at the time of hospital discharge for an initial 
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Medical history   
Chronic kidney disease  46.2 62.1 64.1 <0.05 
Chronic obstructive pulmonary disease  39.5 63.3 57.0 <0.05 
Diabetes mellitus  53.1 70.0 73.3 <0.001 
Heart failure  21.8 54.0 64.0 <0.001 




Hypertension  55.0 73.9 73.3 <0.001 
Peripheral vascular disease  45.6 74.0 62.8 <0.05 
Percutaneous coronary intervention 49.0 81.4 78.6 <0.05 
Prior antiplatelet therapy  52.4 77.3 71.6 <0.001 
Stroke  43.1 57.1 53.5 0.37 
Prior GI Bleeding 36.3 51.5 58.3 0.18 
Peptic Ulcer Disease 46.9 56.2 57.1 0.48 
Teaching hospital  61.0 78.1 78.0 <0.001 
Evidence-based medical therapy 38.9 21.8 21.9 <0.001 
Diagnostic/Interventional Procedure   
Cardiac catheterization  72.9 86.3 83.5 <0.001 
Coronary artery bypass surgery  14.1 32.5 12.8 <0.05 
Percutaneous coronary intervention  89.2 95.7 95.3 <0.001 
Thrombolytic therapy  62.1 75.0 100 0.43 
Hospital Complications  
Cardiogenic shock  73.7 65.2 52.9 0.4 
Heart failure  40.5 56.5 62.4 <0.001 






Table 4. Multivariable-adjusted regression analyses of factors associated with the receipt of DAPT 
at the time of hospital discharge among hospital survivors of an initial acute myocardial infarction 
(Worcester Heart Attack Study) 
 
 Model 1 * Model 2 † Model 3 ‡ 
Characteristics Odds ratio (95% CI)  Odds ratio (95% CI)  Odds ratio (95% CI)  
Age (years)    
55-64 0.62 (0.46 – 0.84) 0.65 (0.48 – 0.89) 0.76 (0.52 – 1.12) 
65-74 0.43 (0.32 – 0.59) 0.48 (0.35 – 0.65) 0.53 (0.36 – 0.80) 
≥75 0.25 (0.19 – 0.33) 0.30 (0.23 – 0.40) 0.70 (0.48 – 1.02) 
Male 1.52 (1.25 – 1.85) 1.51 (1.24 – 1.84) 1.36 (1.05 - 1.76) 
 STEMI 2.30 (1.87 – 2.82) 2.14 (1.74 – 2.64) 1.13 (0.85 – 1.50) 
0.65 (0.51 – 0.84) Prior chronic obstructive 
pulmonary disease 
- 0.60 (0.45 – 0.80) .70 ( .49  1.00) 
Prior chronic kidney disease - 0.88 (0.65 – 1.19) 1.36 (0.95 – 1.97) 
Prior diabetes mellitus - 1.03 (0.82 – 1.29) 1.1 (0.83 – 1.45) 
Prior heart failure - 0.61 (0.44 – 0.85) 0.92 (0.60 – 1.40) 
Prior peripheral vascular disease - 1.04 (0.77 – 1.41) 1.24 (0.85 – 1.80) 
Prior stroke - 0.70 (0.48 – 1.04) 0.88 (0.55 – 1.38) 
Prior GI Bleeding - 0.53 (0.31 – 0.90) 0.68 (0.34 – 1.35) 
Prior Peptic Ulcer Disease - 0.69 (0.41 – 1.15) 0.73 (0.37 – 1.45) 
Teaching hospital - - 1.39 (0.87 - 2.21) 
Evidence-based therapy - - 1.71 (1.32 - 2.23 
Heart Failure post-AMI - - 0.80 (0.60 – 1.10) 
Stroke post-AMI - - 1.46 (0.42 – 5.10) 
Cardiogenic Shock 
 
- - 0.64 (0.29 – 1.40) 
Cardiac Catheterization - - 2.29 (1.65 - 3.16) 
PCI - - 14.60 (10.66 - 19.98) 
 * Model 1: Controlled for age, sex, STEMI, and study year  
† Model 2: Model 1 plus presence of a history of the following co-morbidities: hypertension, diabetes mellitus, chronic kidney disease, heart failure, 
peripheral vascular disease, stroke, chronic obstructive lung disease, GI bleeding, peptic ulcer disease, type of hospital, receipt of evidence-based 
therapy 
‡ Model 3: Model 2 plus hospital development of a STEMI, coronary revascularization procedure, and the development of hospital complications 




Figure 1. Mechanism of action of dual antiplatelet therapy 
 
  
Adopted from: Kandan, Sri Raveen, and Thomas W. Johnson. "Contemporary Antiplatelet Strategies in the Treatment 





Figure 2. Study design flowchart for hospital survivors of AMI in the Worcester Heart Attack 







Figure 3. Trends in the receipt of DAPT at the time of hospital discharge among hospital survivors 
of an initial acute myocardial infarction (Worcester Heart Attack Study). A, by age group; B, by 








Supplementary Table 1. Changing trends in the receipt of DAPT at the time of hospital discharge 
among hospital survivors of an initial acute myocardial infarction, stratified according to PCI use 
(Worcester Heart Attack Study) 
 
Study year                 Odds ratio (95% confidence interval) * 
 PCI (+)      No PCI (-)  
2001 Reference  
2003 
1.77 (0.95; 3.27) 2.19 (1.32; 3.64) 
2005 3.01 (1.47; 6.18) 3.48 (2.05; 5.92) 
2007 5.48 (2.35; 12.81) 4.12 (2.43; 6.97) 
2009 4.09 (1.84; 9.11) 3.01 (1.73; 5.25) 
2011 2.64 (1.29; 5.41) 3.46 (2.05; 5.87) 
 
 
* Adjusted for age, sex, race, previously diagnosed comorbid conditions (hypertension, diabetes, heart failure, chronic kidney disease, peripheral 
vascular disease, stroke, chronic obstructive lung disease, GI bleeding, peptic ulcer disease), hospital development of a STEMI, coronary 
revascularization procedure, type of hospital, receipt of evidence-based therapy, and the development of hospital complications (stroke, heart 






Supplementary Table 2. Changing trends in the receipt of DAPT at the time of hospital discharge 
among hospital survivors of an initial acute myocardial infarction, stratified according to type of 

























* Adjusted for age, sex, race, previously diagnosed comorbid conditions (hypertension, diabetes, heart failure, chronic kidney disease, peripheral 
vascular disease, stroke, chronic obstructive lung disease, GI bleeding, peptic ulcer disease), hospital development of  a STEMI, coronary 
revascularization procedure, type of hospital, receipt of evidence-based therapy, and the development of hospital complications (stroke, heart 
failure, and cardiogenic shock) 
  
Study year  Odds ratio (95% confidence interval)* 
 NSTEMI  STEMI 
2001 Reference  
2003 2.01 (1.23; 3.29) 2.56 (1.30; 5.07) 
2005 3.17 (1.88; 5.33) 4.30 (1.89; 8.86) 
2007 4.51 (2.67; 7.61) 5.98 (2.59; 13.10) 
2009 3.45 (2.05; 5.80) 2.68 (1.14; 6.14) 




Supplementary Table 3. Multivariable-adjusted regression analysis of factors associated with the 
receipt of DAPT at the time of hospital discharge versus antiplatelet monotherapy among hospital 
survivors of an  initial acute myocardial infarction (AMI), stratified according to  type of AMI  
(Worcester Heart Attack Study) 
 
           Odds ratio (95% confidence interval) * 
Characteristics STEMI  NSTEMI  
Age (years)   
55-64 0.76 (0.46 – 1.25) 0.81 (0.42 – 1.54) 
65-74 0.51 (0.31 – 0.84) 0.63 (0.32 – 1.27) 
≥75 0.69 (0.43 – 1.10) 0.79 (0.39 – 1.60) 
Male 1.26 (0.94 – 1.70) 1.79 (1.07 – 2.98) 
Chronic obstructive pulmonary 
disease 
0.73 (0.49 – 1.09) 0.63 (0.29 – 1.38) 
Prior chronic kidney disease 1.34 (0.90 – 2.00) 1.35 (0.53 – 3.46) 
Prior diabetes Mellitus 1.01 (0.73 – 1.40) 1.36 (0.78 – 2.33) 
Prior heart failure 0.89 (0.57 – 1.40) 0.54 (0.20 – 2.33) 
Prior peripheral vascular disease 1.48 (0.98 – 2.24) 1.89 (0.24 – 1.22) 
Prior Stroke 0.76 (0.46 – 1.27) 1.89 (0.62 – 5.84) 
Prior GI Bleeding 2.98 (0.56 – 15.8) 0.44 (0.20 – 0.99)  
Prior Peptic Ulcer Disease 0.65 (0.18 – 2.45) 0.71 (0.31 – 1.61)  
Heart Failure post-MI 0.88 (0.62 – 1.25) 0.62 (0.35 – 1.09) 
Stroke post-MI 1.37 (0.31 – 6.0) 2.47 (0.20 – 30.47) 
Cardiogenic Shock 
 
0.50 (0.12 – 2.11) 0.87 (0.32 – 2.48) 
Cardiac Catheterization 1.94 (1.34 – 2.81) 4.54 (2.26 – 9.12) 
PCI 15.35 (10.33 – 22.8) 12.31 (7.20 – 21.04) 
* Adjusted for age, sex, race, previously diagnosed comorbid conditions (hypertension, diabetes mellitus, heart failure, chronic kidney disease, 
peripheral vascular disease, stroke, chronic obstructive pulmonary disease, GI bleeding, peptic ulcer disease), presence of a history of the following 
co-morbidities: hypertension, diabetes mellitus, chronic kidney disease, heart failure, peripheral vascular disease, stroke, chronic obstructive lung 
disease, GI bleeding, peptic ulcer disease, type of hospital, receipt of evidence-based therapy and hospital development of a STEMI, coronary 




Supplementary Table 4. Multivariable-adjusted regression analysis of factors associated with the 
receipt of DAPT at the time of hospital discharge versus antiplatelet monotherapy among hospital 
survivors of an initial acute myocardial infarction, stratified according to the receipt of a PCI 
(Worcester Heart Attack Study) 
 
           Odds ratio (95% confidence interval) * 
Characteristic PCI  (+) No PCI  (-) 
Age (years)   
55-64 1.10 (0.58 – 1.93) 0.59 (0.34 – 0.92) 
0.335 
0.921 
65-74 0.66 (0.37 – 1.12) 42 (0.25 – 0.71) 
≥75 0.92 (0.47 – 1.79) 41 (0.26 – 0.64) 
Male 1.18 (0.74 – 1.89) 1.47 (1.08 – 1.98) 
Chronic obstructive pulmonary 
disease 
0.77 (0.36 – 1.63) 0.68 (0.45 – 1.03) 
Chronic kidney disease 1.13 (0.48 – 2.63) 1.29 (0.86 – 1.92) 
Diabetes mellitus 0.87 (0.53 – 1.43) 1.23 (0.88 – 1.71) 
Heart failure 0.67 (0.25 – 1.79) 0.91 (0.58 – 1.41) 
Peripheral vascular disease 1.33 (0.58 – 3.02) 1.31 (0.86 – 2.00) 
Stroke 0.67 (0.25 – 1.87) 0.98 (0.61 – 1.59) 
Prior GI Bleeding 0.96 (0.21 – 4.49)  0.64 (0.29 – 1.43)  
Prior Peptic Ulcer Disease 0.45 (0.16 – 1.26)  0.94 (0.42 – 2.11)  
Heart Failure post-MI 0.60 (0.34 – 1.07) 0.84 (0.61 – 1.18) 
Cardiogenic Shock 
 
1.11 (0.31 – 4.03) 0.41 (0.11 – 1.51) 
STEMI 1.24 (0.79– 1.94) 1.07 (0.76 – 1.55) 
 
* Adjusted for age, sex, race, previously diagnosed comorbid conditions (hypertension, diabetes mellitus, heart failure, chronic kidney disease, 
peripheral vascular disease, stroke, chronic obstructive pulmonary disease, GI bleeding, peptic ulcer disease), presence of a history of the following 
co-morbidities: hypertension, diabetes mellitus, chronic kidney disease, heart failure, peripheral vascular disease, stroke, chronic obstructive lung 
disease, GI bleeding, peptic ulcer disease, type of hospital, receipt of evidence-based therapy and hospital development of a STEMI, coronary 
revascularization procedure, and the development of hospital complications (stroke,, heart failure, and cardiogenic shock) 
 
 
